ALXN Quote, Trading Chart, Alexion Pharmaceuticals Inc.
home / stock / alxn / alxn quote
$154.75 Last:
1.19% Change Percent:
$153.42 Open:
$154.75 Previous Close:
$154.81 High:
$153.06 Low:
909,895 Volume:
02/24/2021 01:10:16 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-24 | 153.42 | 154.75 | 154.81 | 153.06 | 909,895 |
| 2021-02-23 | 155.14 | 152.93 | 155.41 | 152.65 | 2,394,547 |
| 2021-02-22 | 155.4 | 154.81 | 155.7 | 154.71 | 3,577,611 |
| 2021-02-19 | 156.84 | 155.51 | 157.3 | 155.42 | 2,056,856 |
| 2021-02-18 | 157.1 | 157.58 | 157.99 | 156.86 | 1,980,347 |
| 2021-02-17 | 157.22 | 157.02 | 158.41 | 156.59 | 2,390,446 |
| 2021-02-16 | 156.88 | 156.69 | 157.345 | 156 | 1,280,101 |
| 2021-02-15 | 156.18 | 158.39 | 158.56 | 156.14 | 1,964,556 |
| 2021-02-12 | 156.18 | 158.39 | 158.56 | 156.14 | 1,956,565 |
| 2021-02-11 | 154.99 | 154.59 | 155.43 | 153.59 | 1,621,082 |
| 2021-02-10 | 156.08 | 154.58 | 156.63 | 154.12 | 1,555,994 |
| 2021-02-09 | 154.51 | 155.27 | 155.8 | 154.44 | 1,920,498 |
| 2021-02-08 | 154.74 | 154.5 | 155.76 | 154.27 | 1,917,242 |
| 2021-02-05 | 155.13 | 153.92 | 155.26 | 153.81 | 2,210,233 |
| 2021-02-04 | 155.35 | 155.59 | 156.2766 | 155.1 | 4,268,080 |
| 2021-02-03 | 155 | 154.74 | 155.5 | 154.2 | 1,894,273 |
| 2021-02-02 | 156.31 | 154.86 | 156.97 | 154.79 | 2,066,230 |
| 2021-02-01 | 156.4 | 155.7 | 156.77 | 155.5 | 4,474,114 |
| 2021-01-29 | 156.47 | 153.33 | 156.82 | 153.24 | 4,334,380 |
| 2021-01-28 | 155.94 | 157.29 | 158.44 | 155.7 | 2,721,509 |
Alexion Pharmaceuticals Inc. Company Name:
ALXN Stock Symbol:
NASDAQ Market:
Alexion Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96 Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021 Received EU approval for ULTOMIRIS ...
-
Having overcome business challenges presented by the COVID-19 pandemic, the stock of Alexion Pharmaceuticals (ALXN) has been hitting new highs. We think it may be wise to bet on the stock now because this company has been receiving multiple regulatory approvals for its products. Headquart...
-
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 before the US financial markets open on February 4, 2021. Given the recently announced agreement to be acquire...